The Latest Breaking News from Biomarin Pharmaceutical

Breakthrough developments, the use of advanced technologies, and rising investments in R&D are some of the factors driving the growth of the biotech industry. Although BioMarin Pharmaceutical (BMRN) showcases strong growth prospects, investors could consider buying even better biotech stocks Amgen (AMGN), Jazz Pharmaceuticals (JAZZ), and Vertex Pharmaceuticals (VRTX). Read…

Activist investor Elliott has reportedly built a $1 billion stake in BioMarin Pharmaceutical, Reuters reported Tuesday as BMRN stock rocketed.

REDWOOD CITY, California — A tech titan and a biotech company revealed plans to chop nearly 300 jobs in the Bay Area, hinting at unsettling prospects for the region’s employment sector.

Biotech stocks have swung sharply higher, buoyed by several factors. Could they be poised to lead the market though the next big upturn?

The European Commission (EC) has granted conditional marketing authorization (CMA) to BioMarin Pharmaceutical’s (NASDAQ:BMRN) lead asset ROCTAVIAN (valoctocogene roxaparvovec) gene therapy for the treatment of severe hemophilia A (congenital Factor VIII deficiency) in adult patients. BioMarin shares traded as high as 2.28 percent, in a range of $91.39 to $93.68…

Analysts have provided the following ratings for Biomarin Pharmaceutical (NASDAQ:BMRN) within the last quarter:

Biomarin Pharmaceutical (NASDAQ:BMRN) is set to give its latest quarterly earnings report on Wednesday, 2022-04-27. Here's what investors need to know before the announcement. Analysts estimate that Biomarin Pharmaceutical will report an earnings per share (EPS) of $0.17.

 

If history is any guide, there may be trouble ahead for shares of Biomarin Pharmaceutical (NASDAQ:BMRN). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.